The Venture Codex

Participated · Seed · May 2026

Rosarium Health provides a platform that coordinates the full lifecycle of home-based interventions, including in-home assessments by occupational and physical therapists, home modification recommendations, and contractor execution such as ramps and stair lifts. The company also automates documentation, prior authorization and claims submission to streamline payments and reimbursement. Rosarium operates a network of more than 800 clinicians and 3,000 contractors across 34 states and is in-network for 1.2 million Medicare and Medicaid lives, with plans to reach 4 million by year end. Financially, the company has raised $9 million to date, including a $6 million seed round led by Kalos Ventures. Rosarium plans to use recent funding to expand partnerships with Managed Medicaid and Medicare Advantage plans, particularly in California and the Northeast, and to scale its network and platform technology. The company’s stated goal is to make the home a reliable, large-scale site of care that reduces costs and improves outcomes for aging and underserved populations.

Participated · Seed · Mar 2026

Flourish Care, founded in 2020, operates a maternal healthcare platform that matches families with credentialed doulas and delivers a hybrid model of in-person and virtual support. The platform powers referrals, care coordination, and insurance reimbursement and integrates into workflows for health plans, obstetrics, hospitals, FQHCs, and community organizations. Flourish Care reports it has supported thousands of families and is available to more than 20 million covered lives through commercial plans and Medicaid. The company is building an AI-driven risk-prediction engine using clinical and community-reported data to identify patients who may benefit from additional support earlier in pregnancy. Flourish Care positions its model as improving maternal outcomes, reducing unnecessary interventions, and lowering costs as states expand reimbursement for doula care.

Participated · Series A · Sep 2025

Lōvu Health operates an AI-powered digital maternal health platform that personalizes care from conception through two years postpartum, combining remote patient monitoring, clinician dashboards, care navigation, and a curated marketplace of third-party vendors. The platform captures fetal heart rate, maternal blood pressure, weight, heart rate, and mental-health assessments in a dynamic dashboard that alerts clinicians to meaningful changes and reduces administrative burden. Lōvu reports clinical impact metrics including earlier identification of preeclampsia for 6% of mothers, detection of depression and anxiety in upwards of 30% of clinical populations, and identification of 57% of mothers on the platform with chronic hypertension. Its marketplace includes more than 50 specialty vendors—doula support, lactation, pelvic floor therapy, mental health and others—and can shorten time to mental-health appointments by up to four months. The company plans to use new funding to expand AI capabilities (including three planned augmentative agents), and to invest in automation, integrations, and headcount as it scales to meet clinician and patient demand. Lōvu positions itself as a care-extension to obstetricians to improve access and outcomes, particularly for underserved and Medicaid populations.

Led · Seed · Jun 2025

RevelAi Health builds a conversational-AI platform that acts as a 24/7 virtual care navigator for orthopedic practices and care organizations, handling evidence-based triage, voice/text outcome surveys, and ambient documentation. The platform converts phone, video, and in-person encounters into structured notes with clinical documentation codes and automated risk flags, and it triggers episode-wide workflows for Principal Care Management, Transitional Care Management, and preoperative optimization. Clinical content and decision logic are continuously refined by an advisory group of board-certified orthopedic surgeons to keep recommendations guideline-concordant. The company says it has already automated thousands of care conversations and positions its product to help providers meet CMS value-based initiatives such as the Transforming Episode Accountability Model. RevelAi aims to reduce readmissions, close care gaps for underserved patients, and simplify quality reporting without adding staff burden. The recently closed seed financing will support deeper EHR and practice-management integrations, expansion of AI-collected outcome surveys and risk pathways, and growth of engineering and research teams.

Participated · Seed · Sep 2024

Canopie provides personalized virtual maternal mental health care including one-on-one behavioral health assessments, care management, on-demand therapeutic programs, and clinician-led virtual classes. Its core on-demand program was developed by perinatal clinical psychologists, physicians, researchers, and new moms and is underpinned by seven meta-analyses and 50 randomized controlled trials. In a recent case study with GuideWell (parent company of Florida Blue), 89% of members engaged in Canopie’s core program, 100% of program completers reported improved mood, and 79% of surveyed members attributed Canopie to increased care-seeking; Black, Latina, and resource-constrained moms were the highest engagers. The company plans to use new funding to expand personalized, insurance-covered virtual mental health care and to address social drivers of health for moms across all risk levels. Canopie is led by Founder and CEO Anne Wanlund and is based in Falls Church, Virginia. The company recently raised a $3.7M Seed round to support that expansion. Canopie delivers evidence-based, automated and personalized mental-health programs tailored to expecting and new mothers. The mobile app builds customized 12-day programs with short audio sessions, mood monitoring, and peer stories to reduce stigma and address barriers like scheduling, time, and cost. The company offers two product lines—prevention/treatment for expecting mothers and one for new mothers—and sells primarily to health plans, integrated delivery networks, and self-insured employers. Services include HIPAA-compliant depression screenings (reimbursable through existing CMS codes), cost-effective customized treatment at a fraction of face-to-face therapy, and referral pathways to mental-health providers. Canopie cites randomized controlled trials and a 2021 study in which 79% of users with depressive symptoms experienced a clinically significant improvement. The company plans to use the VIPC investment to secure early customers in healthcare delivery and validate product readiness for larger-scale deployment.